All content on this website is provided for educational and research purposes only. It does not constitute medical advice or treatment. This article discusses biological mechanisms also observed in laboratory and preclinical research models, so no clinical efficacy or safety for human use is implied. The substances discussed, which are not registered medicines, are not intended for use in humans or animals.

Follistatin 344 peptide

Follistatin 344 is a protein involved in regulating muscle growth and cellular signaling by interacting with members of the transforming growth factor-beta (TGF-β) family.

Follistatin is naturally produced in the body and plays a role in controlling signaling molecules such as myostatin, which influences muscle growth and development.

Follistatin 344 refers to a specific form of the protein studied in research related to muscle biology and regenerative medicine.

How Follistatin 344 peptide works

Follistatin can bind to and inhibit proteins such as myostatin and activins, which are involved in regulating muscle growth and cellular differentiation. Experimental research suggests that follistatin may:

  • inhibit myostatin signaling

  • influence pathways involved in muscle growth and regeneration

  • regulate biological processes related to cell differentiation and tissue repair

Because of these properties, follistatin has been studied in experimental research involving muscle biology and gene therapy.

Clinical trials and evidence

Research involving follistatin has included laboratory studies, animal models, and gene therapy research. Experimental studies have explored:

  • the role of myostatin inhibition in muscle growth

  • gene therapy approaches for muscle-wasting diseases

  • regulation of cell differentiation pathways

Although these studies have provided important insights into muscle biology, therapeutic applications of follistatin remain experimental.

Possible side effects of Follistatin 344:

Because Follistatin 344 influences signaling pathways involved in cell growth and differentiation, potential side effects may be related to changes in these biological processes. Possible or theoretical side effects may include:

  • headache

  • fatigue

  • injection site reactions

  • changes in metabolic signaling pathways

  • unintended effects on cellular growth regulation

Since most research on follistatin has been conducted in laboratory and experimental models, the complete safety profile in humans has not been fully established.

Further clinical research is required to better understand the long-term safety and potential risks associated with this protein.

Follistatin 344 is considered an experimental peptide studied primarily in research and is not approved as a prescription medication by major regulatory authorities. Scientific research involving such compounds should be conducted with appropriate safety precautions and in accordance with applicable laws and regulations in the relevant country.

The purpose of this website is to provide clear, evidence-based information about biologically active compounds often discussed in research, metabolic health, and biohacking communities. The information presented here is educational and should not be considered medical advice.

Follistatin 344
Action: Myostatin inhibition | Category: regulatory protein
Experimental dosage: 50 mcg | Frequency: every 2 days | Timing: freely | Cycle on: 10-30 days — Route: subcutaneous (SC). Stop rules: hold and seek medical advice if moderate/severe adverse effects occur (e.g., escalating nausea/vomiting, dizziness, palpitations, significant blood pressure changes, severe injection‑site reactions, allergic symptoms) or if there is no clear ‘return‑to‑baseline’ window between doses. | Cycle off: 30 days
Effectiveness: ■■■▢▢ | Safety: ■■▢▢▢

Related peptides

Peptides from the same functional group:Follistatin 315, IGF-1 LR3, MGF non PEG, PEG-MGF

Our peptides database

5-Amino-1MQ | AICAR peptide | AOD9604 peptide | Arg-BPC-157 peptide | BPC-157 peptide | CagriSema | Cerebrolysin peptide | CJC-1295 NO DAC peptide | CJC-1295 with DAC peptide | Cortagen peptide | Dihexa peptide | DSIP peptide (Delta Sleep-Inducing Peptide) | Dulaglutide peptide | Epithalon peptide | Exenatide peptide | Follistatin 315 peptide | Follistatin 344 peptide | FOXO4-DRI peptide | GHK-Cu peptide | GHRP-2 peptide | GHRP-6 peptide | Hexarelin peptide | HGH Fragment 176-191 | Humanin peptide | IGF-1 LR3 peptide | Ipamorelin CJC-1295 NO DAC | Ipamorelin peptide | Kisspeptin peptide | KPV peptide | L-Carnitine | Liraglutide peptide | Livagen peptide | LL-37 peptide | Matrixyl peptide | Mazdutide peptide | Melanotan II peptide | Melanotan peptide | MGF peptide (Mechano Growth Factor peptide) | MOD GRF 1-29 | MOTS-C peptide | NAD+ coenzime (Nicotinamide Adenine Dinucleotide) | Oxytocin peptide | P21 peptide | PEG-MGF peptide | Pinealon peptide | PT-141 peptide (Bremelanotide) | PTD-DBM peptide | Retatrutide | Selank peptide | Semaglutide | Semax peptide | Sermorelin peptide | SHLP-2 peptide | SHLP-6 peptide | Somatropin peptide | SS-31 peptide (Elamipretide) | TB-500 peptide | Tesamorelin peptide | Thymosin Alpha 1 peptide | Thymosin beta 4 peptide | Thymosin β10 peptide | Thymulin peptide | Tirzepatide | Vilon peptide
Tagged